ATN framework can be extended to detect frontotemporal degeneration

atn framework can be extended to detect frontotemporal degeneration

Sumary of ATN framework can be extended to detect frontotemporal degeneration:

  • Even so, the development of biomarkers can give patients and their families answers during life: Alzheimer’s disease can be accurately detected via peptides and proteins in a patient’s cerebrospinal fluids (CSF), which can be collected through a lumbar puncture and tested while the patient is alive.
  • In 2018, a new framework suggested combining three Alzheimer’s disease biomarkers in CSF – pathologic amyloid plaques (A), tangles (T), and neurodegeneration (N), collectively called ATN.
  • Biomarkers can fill the gap by providing evidence of whether Alzheimer’s pathology underlies a patient’s symptoms.
  • CSF biomarkers work similarly to a pregnancy test, offering a simple positive or negative result when enough of a substance is detected.
  • But like a pregnancy test, biomarkers for Alzheimer’s disease can provide false negatives or positives.
  • However, to accomplish this, additional biomarkers that can detect other neurodegenerative conditions are critically needed.
  • “While the ATN framework is very exciting and offers much opportunity for patients with Alzheimer’s disease, these biomarkers don’t capture every case of the disease.

Want to know more click here go to source.

From -

Close
Generic selectors
Exact matches only
Search in title
Search in content

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close